Last €48.48 EUR
Change Today +0.285 / 0.59%
Volume 5.0K
MDT On Other Exchanges
Symbol
Exchange
New York
Mexico
Frankfurt
As of 12:11 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

medtronic inc (MDT) Snapshot

Open
€48.06
Previous Close
€48.20
Day High
€48.48
Day Low
€47.68
52 Week High
06/16/14 - €50.76
52 Week Low
09/30/13 - €38.50
Market Cap
47.5B
Average Volume 10 Days
7.6K
EPS TTM
--
Shares Outstanding
979.5M
EX-Date
10/1/14
P/E TM
--
Dividend
€1.22
Dividend Yield
1.72%
Current Stock Chart for MEDTRONIC INC (MDT)

medtronic inc (MDT) Details

Medtronic, Inc. manufactures and sells device-based medical therapies worldwide. It operates through three segments: Cardiac and Vascular Group, Restorative Therapies Group, and Diabetes Group. The Cardiac and Vascular Group’s products include pacemakers; insertable cardiac monitors; implantable defibrillators; leads and delivery systems; ablation products; electrophysiology catheters; products for the treatment of atrial fibrillation; information systems for the management of patients with cardiac rhythm disease management devices; products to reduce surgical site infections; coronary and peripheral stents and related delivery systems; therapies for uncontrolled hypertension; endovascular stent graft systems; heart valve replacement technologies; cardiac tissue ablation systems; and open heart and coronary bypass grafting surgical products. The Restorative Therapies Group offers products for various areas of the spine; bone graft substitutes; biologic products; trauma, implantable neurostimulation therapies, and drug delivery systems for the treatment of chronic pain, movement disorders, obsessive-compulsive disorder, overactive bladder, urinary retention, fecal incontinence, and gastroparesis; products to treat conditions of the ear, nose, and throat; and systems that incorporate advanced energy surgical instruments. It also manufactures and sells image-guided surgery and intra-operative imaging systems. The Diabetes Group’s products include insulin pumps; continuous glucose monitoring systems; insulin pump consumables; and Web-based therapy management software solutions. The company serves hospitals, physicians, clinicians, and patients in approximately 140 countries. Medtronic, Inc. was founded in 1949 and is headquartered in Minneapolis, Minnesota.

49,247 Employees
Last Reported Date: 06/20/14
Founded in 1949

medtronic inc (MDT) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.5M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $774.9K
Executive Vice President and Group President ...
Total Annual Compensation: $724.9K
Executive Vice President and Group President ...
Total Annual Compensation: $675.1K
Chief Human Resources Officer and Senior Vice...
Total Annual Compensation: $781.7K
Compensation as of Fiscal Year 2014.

medtronic inc (MDT) Key Developments

Medtronic Receives Clearance for the SHILLA(TM) Growth Guidance System

Medtronic, Inc. announced the 510(k) clearance and launch of the SHILLA(TM) Growth Guidance System. The system is designed for treatment of skeletally immature pediatric patients less than 10 years of age diagnosed with severe, progressive, life-threatening, early-onset spinal deformities. The SHILLA(TM) Growth Guidance System is a new growth-sparing technology that allows correction of the deformity while maintaining the corrections over time, minimizing the need for periodic lengthening procedures. This is different than current operative treatments, which are distraction based systems that require lengthening every 6 to 9 months. The SHILLA(TM) Growth Guidance System utilizes a unique non-locking set screw at the proximal and distal portions of the construct's rods. This specific feature allows the rod to slide through the screw heads as the child's spine grows, while still providing correction of the spinal deformity.

Medtronic Announces First Implants in Global Trial of Cardiac Resynchronization Therapy

Medtronic, Inc. announced the first implants in a clinical trial that will compare patient and healthcare system outcomes - including patient mortality and hospitalizations - in heart failure patients who have cardiac resynchronization therapy (CRT) devices with the AdaptivCRT(R) feature enabled versus patients receiving standard CRT. The AdaptResponse trial will assess the superiority of the AdaptivCRT algorithm, which preserves normal heart rhythms and automatically adjusts to patients' needs to customize therapy; it is expected to be the larger trial of CRT to date, enrolling approximately 3,000 patients worldwide. The primary endpoint of the AdaptResponse trial is a combination of all-cause mortality and the rate of medical intervention for worsening heart failure (decompensation). The trial also will examine the incidence of atrial fibrillation (AF) in enrolled patients; other secondary endpoints will assess patient quality of life measures as well as cost-effectiveness of CRT devices with the AdaptivCRT feature relative to standard CRT. Patients will receive a CRT-pacemaker or CRT-defibrillator equipped with the AdaptivCRT algorithm, and will be randomized 1:1 to either treatment (aCRT ON) or control (aCRT OFF) groups. Patients will be followed at three and six months after randomization, and then every six months until trial closure.

Medtronic Announces FDA Approval and Availability of Viva CRT-P Pacemaker in U.S

Medtronic announced that its Viva CRT-P pacemaker received FDA approval for indicated patients with heart failure or atrioventricular block.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDT:GR €48.48 EUR +0.285

MDT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $42.24 USD -0.11
Allergan Inc/United States $163.68 USD +1.57
Astellas Pharma Inc ¥1,498 JPY -25.00
Becton Dickinson and Co $117.17 USD +0.69
Covidien PLC $86.83 USD +0.13
View Industry Companies
 

Industry Analysis

MDT

Industry Average

Valuation MDT Industry Range
Price/Earnings 21.6x
Price/Sales 3.7x
Price/Book 3.3x
Price/Cash Flow 19.1x
TEV/Sales 2.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDTRONIC INC, please visit www.medtronic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.